Drugs / Pediococcus acidilactici
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07371325 | Sep 2024 → Jan 2026 | metabolic disease, schizophrenia 1 | Manuel Jesús Cuesta Zurita | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pediococcus acidilactici | “Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants” NCT07371325 ↗ |
| Known as | pA1cHI | “Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants” NCT07371325 ↗ |
| Modality | Other / unclassified | “add-on postbiotic (Pediococcus acidilactici, pA1c®HI)” NCT07371325 ↗ |